Navigation Links
VIA Pharmaceuticals' DGAT1 Inhibitors Featured in American Diabetes Association Poster Presentation
Date:6/4/2009

Preclinical Data Reported by Roche at 69th Scientific Sessions

SAN FRANCISCO, June 4 /PRNewswire-FirstCall/ -- VIA Pharmaceuticals, Inc. (Nasdaq: VIAP), a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease, announced today that preclinical data related to diacylglycerol acyl transferase - 1 (DGAT1) inhibitors will be presented in a poster presentation at the 69th Scientific Sessions of the American Diabetes Association June 6, 2009 in New Orleans, LA. The poster will be presented by Roche (SWX: ROG), who licensed its DGAT1 inhibitors exclusively to VIA in December 2008. Dr. Rebecca Taub, Sr. Vice President Research & Development of VIA and a co-author on the poster, managed development of the DGAT1 program at Roche prior to joining the VIA management team.

    The presentation details are as follows:
       Date/Time: Saturday June 6, 2009
                  11:30AM - 1:30PM
                   6:15PM - 7:30PM
       Location: Ernest N. Morial Convention Center
       Session: Insulin Action - Metabolism
       Title: Can DGAT Inhibition Improve Insulin Sensitivity? (Poster 1279-P)

DGAT1 (diacylglycerol acyl transferase-1) is an enzyme that catalyzes triglyceride synthesis and fat storage. Triglycerides are the principal component of fat, which is the major repository for storage of metabolic energy in the body. Overweight and obese individuals have significantly greater triglyceride levels, making them more prone to diabetes and its associated metabolic complications. DGAT1 inhibitors are believed to be an innovative class of compounds that modify lipid metabolism. In studies of obese animals, DGAT1 inhibitors have been shown to induce weight loss and improve insulin sensitization, glucose tolerance and lipid levels. These obs
'/>"/>

SOURCE VIA Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Optimer Pharmaceuticals to Present at June 2009 Investor Conferences
2. Amylin Pharmaceuticals to Present at Goldman Sachs Annual Global Health Care Conference
3. Optimer Pharmaceuticals Announces Lower Recurrence Rates for Fidaxomicin Versus Vancocin(R) in Subgroup Analyses from Its Phase 3 Study for the Treatment of CDI
4. Raptor Pharmaceuticals Doses First Patient in Phase 2b Clinical Trial of DR Cysteamine for Cystinosis
5. Peregrine Pharmaceuticals Presents Promising Data From Its Phase II Bavituximab Breast Cancer Trial at 2009 ASCO Annual Meeting
6. Valeant Pharmaceuticals Reports Encouraging Final Results With Taribavirin Phase IIb Study
7. OncoGenex Pharmaceuticals Announces OGX-011 Treatment Provides Survival Benefit in Randomized Phase 2 Trial in Advanced Metastatic Prostate Cancer
8. OncoGenex Pharmaceuticals Announces OGX-427 Treatment Demonstrates Safety, Evidence of Declines in Circulating Tumor Cells and Reductions in Tumor Markers in a Phase 1 Cancer Trial
9. Angiotech Pharmaceuticals announces FDA approval of next-generation TAXUS(R) Liberte(R) Atom(TM) Stent system
10. Biostar Pharmaceuticals, Inc. Reports Continued Revenues and Earnings Growth in First Quarter of 2009
11. OncoGenex Pharmaceuticals to Webcast ASCO Reception on May 30, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... Va. , March 5, 2015   HX360 ... as semi-finalists in the HX360 Innovation Challenge ... entries, will compete to be chosen as one of ... panel of senior health system executives and venture capitalists ... HX360 Innovation Challenge takes place at the 2015 HIMSS ...
(Date:3/5/2015)... York (PRWEB) March 05, 2015 LifeCell ... to be able to get an Advanced Semen Analysis ... stress, blaming and guessing are all risk factors for ... the woman is the source of the infertility. Infertility ... LifeCell Dx has the simplest, least complicated and ...
(Date:3/5/2015)... 2015 Plant disease specialists from around ... the Annual Meeting of The American Phytopathological Society. ... online now at APSnet.org/meet . , The Preliminary ... to be held August 1-5, 2015 in Pasadena, California, ... Trips, Workshops, and committee meetings, all carefully balanced to ...
(Date:3/5/2015)... Springs, FL (PRWEB) March 05, 2015 ... Damm for the position of Vice President of Managed ... managed care relationships for one of the nation’s leading ... brings more than 15 years of specialty pharmacy and ... Damm worked with Raptor Pharmaceuticals, Vertex Pharmaceuticals, and Pfizer. ...
Breaking Biology Technology:HX360 Announces Sixteen Innovation Challenge Semi-finalists Competing To Deliver Solutions That Improve The Patient Experience 2HX360 Announces Sixteen Innovation Challenge Semi-finalists Competing To Deliver Solutions That Improve The Patient Experience 3HX360 Announces Sixteen Innovation Challenge Semi-finalists Competing To Deliver Solutions That Improve The Patient Experience 4LifeCell Dx Offers New Option to Veterans with Infertility 2LifeCell Dx Offers New Option to Veterans with Infertility 3American Phytopathological Society Announces Annual Meeting Daily Schedule 2BioPlus Specialty Pharmacy Announces Hiring of New Vice President of Managed Care: Jamie Damm 2
... 2011 Palatin Technologies, Inc. (NYSE Amex: PTN ... 23rd Annual OC Growth Stock Conference on Tuesday, March 15, ... held at the Ritz Carlton Laguna Niguel in Dana Point, ... Executive Officer of Palatin Technologies, will provide an update on ...
... 2011 AccessClosure, Inc., the U.S. market segment ... from the first published study* (Journal of NeuroInterventional ... different vascular closure devices (VCD) as the primary ... the discomfort associated with the Mynx 5F Vascular ...
... UBM Live and its sister company, UBM Japan ... and new developments taking place at the tenth anniversary of ... 18-20 April, 2011 at the Big Sight Exhibition Center in ... P-MEC Japan, which covers Pharma machinery and equipment, ICSE Japan, ...
Cached Biology Technology:Significant Reduction in Pain With the Mynx Vascular Closure Device Versus Angio-Seal Device 2Significant Reduction in Pain With the Mynx Vascular Closure Device Versus Angio-Seal Device 3UBM Announces Content for 10th Annual Japanese Pharma & Bio Events 2UBM Announces Content for 10th Annual Japanese Pharma & Bio Events 3UBM Announces Content for 10th Annual Japanese Pharma & Bio Events 4
(Date:3/5/2015)... In Brazil , cloud computing ... these solutions and 42 percent planning to invest in them ... percent of the companies will be investing in these solutions ... companies in the region are currently opting for the private ... command significant attention in the coming years. This trend is ...
(Date:3/4/2015)... 2015 Research and Markets ( ... "Global Biometrics Market Forecast and Opportunities, 2020" ... market for biometric authentication systems is projected to ... 2020 The driving forces for this ... government projects and constant development in technology. In ...
(Date:3/3/2015)... , March 3, 2015 Cryoport, ... of advanced cryogenic logistics solutions for the ... stem cells, cell lines, clinical research organizations, ... today announced the expansion of its relationship ... ("Fred Hutch") Clinical Research Division with ...
Breaking Biology News(10 mins):Two of Every Three Brazilian Companies will have Invested in Cloud by 2015, Finds Frost & Sullivan 2Two of Every Three Brazilian Companies will have Invested in Cloud by 2015, Finds Frost & Sullivan 3Two of Every Three Brazilian Companies will have Invested in Cloud by 2015, Finds Frost & Sullivan 4Global Biometrics Market Forecast and Opportunities, 2020 2Global Biometrics Market Forecast and Opportunities, 2020 3Cryoport, Inc. Expands Support of Fred Hutchinson Cancer Research Center's Clinical Research Division 2Cryoport, Inc. Expands Support of Fred Hutchinson Cancer Research Center's Clinical Research Division 3
... del Toro Research Station and Galeta Point Marine ... and a major coral bleaching event in the ... Atmospheric Administration, NOAA, issued an advisory in July ... Caribbean region, there had been no clear indication ...
... conference held in Brussels today, the International Osteoporosis Foundation (IOF), ... Group called on health care professionals and health policy officials ... call to action was made at the launch of a ... World Osteoporosis Day on October 20, 2010. Taking ...
... Gardeners could help maintain bumblebee populations by growing plants with ... to field observations of the common snapdragon, Antirrhinum majus ... Bees are important pollinators of crops as well as ... institute of the BBSRC, is committed to research that can ...
Cached Biology News:Smithsonian reports regional sea temperature rise and coral bleaching event in Western Caribbean 2IOF campaign puts spotlight on vastly under-diagnosed and under-treated spinal fractures 2Landing lights for bumblebees 2
Anti-MMP-19 (RASI), carboxy terminal region; rabbit host...
Rabbit anti MMP-13, Hinge Region MMP-13 Hinge Region...
Rabbit polyclonal to ATF4 (phospho S245) ( Abpromise for all tested applications). Antigen: Synthetic phosphopeptide derived from human ATF4 around the phosphorylation site of Serine 245. En...
Evolutionarily conserved signaling intermediate in Toll pathway...
Biology Products: